2012_Citeline_Pharma_RD_Annual_Review

2012_Citeline_Pharma_RD_Annual_Review

ID:40554553

大?。?.96 MB

頁數(shù):14頁

時(shí)間:2019-08-04

2012_Citeline_Pharma_RD_Annual_Review_第1頁
2012_Citeline_Pharma_RD_Annual_Review_第2頁
2012_Citeline_Pharma_RD_Annual_Review_第3頁
2012_Citeline_Pharma_RD_Annual_Review_第4頁
2012_Citeline_Pharma_RD_Annual_Review_第5頁
資源描述:

《2012_Citeline_Pharma_RD_Annual_Review》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。

1、PharmaR&DAnnualReview2012IanLloyd,CitelineEditorialDirectorMayisthetimewhenCiteline’sAnnualReviewoftrendsinpharmaceuticalR&Distraditionallyconducted.Itisausefulopportunitytopauseandreflectonhowtheindustryiscontinuingtoevolve,andisalsothetimewhenwetakethe

2、annualsnapshotofourdatatoprovideanewtimepointforevaluatingtrendsfromourPharmaprojectsPipelinedrugintel-ligenceservice.Inthisarticle,weexaminethedatafor2012,lookathowithaschangedsince2011,andtrytoputtheinformationintosomesortofcontext.Someofthekeypointsco

3、veredinthisreportinclude:?SizeablegrowthintheoverallR&Dpipeline?GSKreplacesPfizerasthecompanywithmostdrugsindevelopment?Astandoutyearfornewactivesubstanceslaunches?IncreaseinR&Damongstart-upandnichecompanies?PromisinggrowthofdrugsincrucialPhaseIIItrials?

4、StrikingaccelerationinoncologyresearchExaminingtheoverallnumberofActivedrugsintheSowhatdoesthisapparentpipelinegrowthmean?Onepipelineisalwaysagoodplacetostart,asitgivesanthingwhichisalwaysdifficultistheteasingapartofrealoverallflavourofthedirectioninwhic

5、hthingsareworldchangesversustheeffectonthefiguresofheaded.Andthisyear,thereisacheeringincreaseinimprovededitorialpracticesanddetection.Clearly,weevidence.Afterthefiguresstagnatedfrom2010to2011,atCitelinearecontinuouslystrivingtoimproveourthe2012totalnumb

6、erofR&Ddrugsisupto10,452,aprocessestomakeourdataincreasinglycomprehensive,7.6%increasefromlastyear’sfigure.Leavingasidetheandthisyearhasbeennoexception.However,itseems2007-2008rise,whichissomethingofanaberrationhighlyunlikelythatthiswouldaccountforanincr

7、easeascausedbythebringingtogetherofdrugdatafromourlargeas739drugs.Ourbestguesswouldbethatbetteroriginaldatabasewiththatofthethennewly-acquireddatacollectionmightaccountfor2-3.5%ofthisincrease,Citelinedatabaseofclinicaltrials(Trialtrove),thiswhichwouldsti

8、llleaveasizeablegrowthintheoverallrepresentsthelargestincreaseinpercentagetermsreportedpipeline,notbadinaneraofausterity.Sooursince2003-2004’s9.0%.reviewof2012kicksoffonapositivenote,andwe’llFigure1:ToTalSizeoFThepipeline2

當(dāng)前文檔最多預(yù)覽五頁,下載文檔查看全文

此文檔下載收益歸作者所有

當(dāng)前文檔最多預(yù)覽五頁,下載文檔查看全文
溫馨提示:
1. 部分包含數(shù)學(xué)公式或PPT動(dòng)畫的文件,查看預(yù)覽時(shí)可能會(huì)顯示錯(cuò)亂或異常,文件下載后無此問題,請(qǐng)放心下載。
2. 本文檔由用戶上傳,版權(quán)歸屬用戶,天天文庫負(fù)責(zé)整理代發(fā)布。如果您對(duì)本文檔版權(quán)有爭議請(qǐng)及時(shí)聯(lián)系客服。
3. 下載前請(qǐng)仔細(xì)閱讀文檔內(nèi)容,確認(rèn)文檔內(nèi)容符合您的需求后進(jìn)行下載,若出現(xiàn)內(nèi)容與標(biāo)題不符可向本站投訴處理。
4. 下載文檔時(shí)可能由于網(wǎng)絡(luò)波動(dòng)等原因無法下載或下載錯(cuò)誤,付費(fèi)完成后未能成功下載的用戶請(qǐng)聯(lián)系客服處理。
相關(guān)文章
更多
相關(guān)標(biāo)簽